We investigate value-based clinical trial design by applying a Bayesian decisiontheoretic model of a sequential experiment to data from the ProFHER pragmatic trial. In the first applied analysis of its kind to use research cost data, we show that the model’s stopping policy would have stopped the trial early, saving about 5% of the research budget (approximately £73,000). A bootstrap analysis based on generating resampled paths from the trial data suggests that the trial’s expected sample size could have been reduced by approximately 40%, saving an expected 15% of the budget, with 93% of resampled paths making a decision consistent with the result of the trial itself. Results show how substantial benefits to trial cost stewardship may be ac...
Clincal trial designs often incorporate a sequential stopping rule to serve as a guide in the early ...
The basic premise of this thesis is that Bayesian Decision Theory (BDT) can and should be used to so...
Current practice for sample size computations in clinical trials is largely based on frequentist or ...
We investigate value-based clinical trial design by applying a Bayesian decisiontheoretic model of a...
Background/Aims: There is growing interest in the use of adaptive designs to improve the efficiency ...
A decision maker confronted with the task of designing a clinical trial has to consider a multitude ...
Introduction Adaptive designs allow changes to an ongoing trial based on prespecified early examina...
Group sequential stopping rules are often used as guidelines in the monitoring of clinical trials in...
We propose a class of phase II clinical trial designs with sequential stopping and adaptive treatmen...
We propose a Bayesian decision theoretic model of a fully sequential experiment in which the real-va...
We solve a Bayesian decision-theoretic model of a sequential experiment in which the real-valued pri...
The clinical trials that provide evidence for new cancer treatments often fall sort of providing ade...
Supplemental material, sj-pdf-1-ctj-10.1177_17407745211032909 for Cost-effective clinical trial desi...
In the conduct of sequential clinical trials, primary statistical issues include design, monitoring ...
We present a Bayes sequential economic evaluation model for health technologies in which an investig...
Clincal trial designs often incorporate a sequential stopping rule to serve as a guide in the early ...
The basic premise of this thesis is that Bayesian Decision Theory (BDT) can and should be used to so...
Current practice for sample size computations in clinical trials is largely based on frequentist or ...
We investigate value-based clinical trial design by applying a Bayesian decisiontheoretic model of a...
Background/Aims: There is growing interest in the use of adaptive designs to improve the efficiency ...
A decision maker confronted with the task of designing a clinical trial has to consider a multitude ...
Introduction Adaptive designs allow changes to an ongoing trial based on prespecified early examina...
Group sequential stopping rules are often used as guidelines in the monitoring of clinical trials in...
We propose a class of phase II clinical trial designs with sequential stopping and adaptive treatmen...
We propose a Bayesian decision theoretic model of a fully sequential experiment in which the real-va...
We solve a Bayesian decision-theoretic model of a sequential experiment in which the real-valued pri...
The clinical trials that provide evidence for new cancer treatments often fall sort of providing ade...
Supplemental material, sj-pdf-1-ctj-10.1177_17407745211032909 for Cost-effective clinical trial desi...
In the conduct of sequential clinical trials, primary statistical issues include design, monitoring ...
We present a Bayes sequential economic evaluation model for health technologies in which an investig...
Clincal trial designs often incorporate a sequential stopping rule to serve as a guide in the early ...
The basic premise of this thesis is that Bayesian Decision Theory (BDT) can and should be used to so...
Current practice for sample size computations in clinical trials is largely based on frequentist or ...